Honasa Buys 58% of Fluence Pharma for Rs 135 Cr, Launches Honasa Health for Nutraceuticals
Mamaearth parent Honasa Consumer is acquiring 58% of Fluence Pharma at a Rs 135 crore enterprise value, with the remaining stake to be absorbed over 5-7 years. It has also incorporated B2C subsidiary Honasa Health to enter the nutraceuticals category, signaling a push beyond personal care.
What happened
Honasa Consumer (Mamaearth parent) approved acquiring 58% of Fluence Pharma at Rs 135 crore EV, with rest absorbed over 5-7 years, and incorporated B2C
Key facts
- 58% stake
- Rs 135 crore
- 42% over 5-7 years
- Advit Jewels IPO 11.18x day 1
- Waterways Leisure 19% day 1
Why this matters
The phased 58%-now, rest-over-5-7-years structure at Rs 135 Cr EV is a playbook worth studying for de-risked category entry through a founder-aligned earn-in.